Medical Simulation Medical Graphic
Medical Animation | MOA | Medical Illustration | Holo 3D | General 3D | Video Game Development | Contact

Biotechnology Animations – Biotechnology Illustrations

Clinical Animations / Trial Animations

Clinical Studies Animated Method of Action Video

Medical Animation Studio produces clinical animations and clinical illustrations.  Custom 3d trail illustrations and clinical illustrations for e learning can also be produced.   Biotechnology animations and biotechnology illustrations created for biotech companies and biotechnology marketing companies.
Biotechnology animated method of action video. 
Dr Nano
Reshaping the future of global clinical trials practice
Researchers at the University of Liverpool have developed a new international guideline to help standardise how results from clinical trial studies are reported.
Investigational immunotherapy was safe, tolerable, and showed some activity against melanoma
The investigational immunotherapeutic IMC-20D7S was safe, well tolerated, and showed signs of modest clinical activity for patients with advanced melanoma, according to results from a...
Positive pivotal Phase 3 data announced demonstrating investigational Elagolix reduced endometriosis-associated pain
AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc.
Depression could be treated with anti-inflammatory drugs
A new meta-analysis finds a new class of drugs used to treat inflammation in autoimmune diseases may also be an effective treatment for depression.
The placebo effect: Knowingly taking sham pills may reduce chronic pain
New study suggests it is not the expectation that a 'dummy pill' is real that elicits the placebo effect, but rather the ritual associated with taking it.
Caffeine did not induce arrhythmia in trial with heart failure patients
A trial where heart failure patients ingested 500 mg caffeine over 5 hours found no raised risk of arrhythmic episodes, even during treadmill stress test.
Breast cancer drug shows potential in patients with skin metastases
A study presented at the ESMO Congress reveals how the drug tucatinib led to a reduction in skin metastases for patients with breast cancer.
Cabozantinib improves progression-free survival in metastatic renal cell carcinoma
Cabozantinib significantly improves progression-free survival and response rate in patients with metastatic renal cell carcinoma compared to sunitinib, according to research presented at the ESMO...
Custirsen shows no survival benefits in metastatic prostate cancer
A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no...
MEK inhibition in KRAS-mutant non-small-cell lung cancer (NSCLC) did not improve survival
MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to data...
Greater patient selection may be needed for first line nivolumab to improve progression-free survival in advanced lung cancer
Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a...
Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression
Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial...
Head and neck cancer: Immunotherapy drug a 'game-changer' for survival
A phase III trial of patients with head and neck cancer reveals the immunotherapy drug nivolumab greatly extended survival, compared with chemotherapy.
Reporting of adverse events in targeted therapy and immunotherapy trials is "suboptimal"
A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and...
Phase 3 results for Sun Pharma's investigational psoriasis medicine, tildrakizumab
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in...
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2016
Content Management / Website Design by Tresware